Study of ALN-ANG3 and Evinacumab for Diabetic Kidney Disease
This study is looking at two experimental drugs, ALN-ANG3 and evinacumab, for adults with diabetic kidney disease (DKD). The main goal is to see how safe and effective these drugs are. Researchers will measure changes in your urine albumin to creatinine ratio (UACR), a marker for kidney damage, over 24 weeks. You might be able to join if you are 18 to 80 years old, have type 2 diabetes, and your blood sugar (HbA1c) and kidney function (eGFR) are within specific ranges. The study also aims to understand potential side effects and how the drugs move through your body.
- Study design
- This interventional study plans to enroll 270 participants. It uses ALN-ANG3 and evinacumab, along with placebos, meaning some participants will receive an inactive substance.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at Week 24, indicating a follow-up period of at least 24 weeks for this measurement.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
At a glance
Conditions
Where it's being run
58 sites across 17 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percent change in Urine Albumin to Creatinine Ratio (UACR)Baseline to Week 24